Incidence of Unresectable Cases of Cervical Cancer

Incidence of Unresectable Cases of Cervical Cancer in Gyne-oncology Unit of Alexandria University Hospital and Its Relation to Pathological Types, Grading and Lymph Vascular Space Invasion

Objective : to calculate the incidence of unresectable cases of cervical cancer in gyne-oncology unit of Alexandria university hospital and to indentify its relation to pathological types, grading and lymph vascular space invasion.

Patients and methods: 70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion

Study Overview

• Status: Completed
• Conditions: Cervical Cancer
• Intervention / Treatment: Diagnostic test: clinical and radiological staging, pathological types, grading and lymphovascular space invasion

• Study Type: Observational
• Enrollment (Actual): 70

Contacts and Locations

Study Locations

• Egypt
  • Alexandria, Egypt
    • Hossam Hassan El Sokkary

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

random cases of cervical cancer

Description

Inclusion Criteria:

• cervical cancer

Exclusion Criteria: none

-

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
clinical and radiological staging	70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion.	10 days

Collaborators and Investigators

• Sponsor: HOSSAM ALSUKARI

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 1, 2019
• Primary Completion (ACTUAL): July 31, 2022
• Study Completion (ACTUAL): August 31, 2022

Study Registration Dates

• First Submitted: September 8, 2022
• First Submitted That Met QC Criteria: September 8, 2022
• First Posted (ACTUAL): September 13, 2022

Study Record Updates

• Last Update Posted (ACTUAL): September 13, 2022
• Last Update Submitted That Met QC Criteria: September 8, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Uterine Cervical Neoplasms
• Other Study ID Numbers: SOKKARY10

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No